CompletedPhase 2

Tigecycline for Treatment of Rapidly Growing Mycobacteria

United States8 participantsStarted 2002-04

Plain-language summary

To determine the safety, tolerance, and efficacy of Tigecycline when given daily to patients with rapidly growing mycobacterial disease (especially M.abscessus).

Who can participate

Age range10 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Positive cultures for rapidly growing mycobacteria * Patients who have drug resistant isolates or are intolerant of macrolides or have serious infections unresponsive to currently available drugs * Adults and children 10 years of age and older * Pretreatment isolate of M. avium complex available for MIC determination * Available for followup appointments Exclusion Criteria: * History of tetracycline allergy * If a menstruating female, not pregnant and on adequate birth control

What they're measuring

Clinical and microbiological outcomes such as clinical symptoms and laboratory cultures

Timeframe: 6 mos

Trial details

NCT IDNCT00600600

SponsorThe University of Texas Health Science Center at Tyler

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2010-04

View on ClinicalTrials.gov More Mycobacterium Abscessus Lung Disease trials